Pimavanserin Moves Toward First-Line Use for Parkinson's Psychosis
Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.
Staff members have no financial relationships with companies related to this material.
Compiled by Carlat Editorial Staff and Reviewed by the Editor-in-Chief and the Editorial Board.
Staff members have no financial relationships with companies related to this material.
Alice Flaherty, MD, PhD.
Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.
Dr. Flaherty has no financial relationships with companies related to this material.
Maureen C. Nash, MD.
Medical Director, Providence ElderPlace PACE Oregon. Co-editor, Neurocognitive Behavioral Disorders: An Interdisciplinary Approach to Patient-Centered Care (Springer; 2019). All comments are Dr. Nash’s personal views and not those of any organization.
Dr. Nash has no financial relationships with companies related to this material.
Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.
James Black, MD. Dr. Black, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.